BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32693114)

  • 1. Targeting BET bromodomain proteins in cancer: The example of lymphomas.
    Spriano F; Stathis A; Bertoni F
    Pharmacol Ther; 2020 Nov; 215():107631. PubMed ID: 32693114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET Inhibitors as Anticancer Agents: A Patent Review.
    Ali I; Choi G; Lee K
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):340-364. PubMed ID: 28786345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
    Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
    Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
    [No Abstract]   [Full Text] [Related]  

  • 7. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BET bromodomain proteins in solid tumors.
    Sahai V; Redig AJ; Collier KA; Eckerdt FD; Munshi HG
    Oncotarget; 2016 Aug; 7(33):53997-54009. PubMed ID: 27283767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
    Yang CY; Qin C; Bai L; Wang S
    Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
    Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury.
    Rudman MD; Choi JS; Lee HE; Tan SK; Ayad NG; Lee JK
    Exp Neurol; 2018 Nov; 309():181-192. PubMed ID: 30134146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
    Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
    Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.
    Deeney JT; Belkina AC; Shirihai OS; Corkey BE; Denis GV
    PLoS One; 2016; 11(3):e0151329. PubMed ID: 27008626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Functions of BET Proteins in Gene Transcription of Biology and Diseases.
    Cheung KL; Kim C; Zhou MM
    Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.